Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Intratumoural administration of cisplatin in slow-release devices

I. Tumour response and toxicity

  • 59 Accesses

  • 28 Citations

Summary

In this study we investigated the effect of the incorporation of cisplatin in slow-release systems on tumours response and animal toxicity after intratumoural (i.t.) administration. Solid slow-release rods with incorporated cisplatin were prepared either from starch or from three different polyether-hydrogel formulations. In vitro release rates from these rods were widely different. With the starch system, approximately 100% release was obtained in 2 h. For the hydrogel formulations, release was approximately 100% in 1 day for a formulation with 40% water uptake (T3), 45% within 4 days for a formulation with 14% water uptake (T2) and 8% within 4 days for a formulation with 4% water uptake (T1). The slow-release rods containing graded amounts of cisplatin were implanted i.t. in s.c. RIF1 murine tumours. The i.t. administration of cisplatin in starch rods did not reduce animal toxicity or increase tumour response relative to i.t. injections of cisplatin in solution. For the hydrogel rods, the tumour response and animal toxicity for a given dose of cisplatin decreased with decreasing release rate. Higher doses of cisplatin could therefore be delivered with the slower-releasing hydrogel formulations. The slowest-release hydrogel rods (T1) had very little effect on either tumour (growth delay) or host (animal weight loss), even at eisplatin doses 8 times that tolerated as an i.p. injection. The fast (T3)-and intermediate (T2)-release hydrogel rods resulted in dose dependent tumour growth delays that were longer than those obtained with i.p. or i.t. administration of cisplatin. The highest response, a tumour growth delay of 55 days, was obtained with the intermediate-release hydrogel rods (T2) at a cisplatin dose of 40 mg/kg. Analysis of tumour growth delay for a given level of toxicity indicated that the intermediate-release formulation (T2) was slightly better than the fast-release formulation (T3) and confirmed the therapeutic advantage of i.t. implants over systemic therapy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Andrews PM, Johnson JL Jr (1989) Regional chemotherapy in an experimental medel of Wilms' tumour in rats. Cancer Chemother Pharmacol 23: 31

  2. 2.

    Arfors KE, Forsberg JO, Larsson B, Lewis DH, Rosengren B, Odman S (1976) Temporary intestinal hypoxia induced by degradable microspheres. Nature 262: 500

  3. 3.

    Baker R (1987) Controlled release of biologically active agents. Wiley Interscience, New York, p 56

  4. 4.

    Bamba M, Puiseux F, Marty JP, Carstensen JT (1979) Release mechanisms in gelforming sustained release preparations. Int J Pharmacol 2: 307

  5. 5.

    Bast RC, Segerling M, Ohanian SH, Greene SL, Zbar B, Rapp HJ, Borsos T (1976) Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. JNC 56: 829

  6. 6.

    Begg AC (1987) Principles and practice of the tumor growth delay assay. In: Kellman RF (ed) Rodent tumor models in experimental cancer therapy Pergamon Press, Oxford, pp 114–121

  7. 7.

    Begg AC, Van der Kolk PJ, Dewit L, Bartelink H (1986) Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int J Radial Biol 50: 871

  8. 8.

    Begg AC, Bartelink H, Stewart FA, Brown DM, Luck EE (1988) Improvement of differential toxicity between tumor and normal tissues using intratumoral injection with or without a slow-drug-release matrix system. NCI Monogr 6: 133

  9. 9.

    Bier J, Benders P, Wenzel M, Bitter K (1979) Kinetics of [57Co]-bleomycin in mice after intravenous, subcutaneous and intratumoral injection. Cancer 44: 1194

  10. 10.

    Brown JM, Twentyman PR, Zamvil SS (1980) Response of the RIF-1 tumor in vitro and in C3H/Km mice to X-irradiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. JNCI 64: 605

  11. 11.

    Dewit L, Begg AC, Köhler Y, Stewart FA, Bartelink H (1985) Influence ofcis-diamminedichloroplatinum(II) on mouse duodenal crypt stem cell survival after multifraction X-ray treatment. Int J Radiat Oncol Biol Phys 11: 1809

  12. 12.

    Edman P, Arturson P, Laakso T, Sjöholm I (1987) Poly(acryl)starch microspheres as drug carrier systems. In: Illum L, Davis SS (eds) Polymers in controlled drug delivery. Wright, Bristol, p 87

  13. 13.

    Ensminger WD, Gyves JW (1984) Regional cancer chemotherapy. Cancer Treat Rep 68:101

  14. 14.

    Hecquet B, Chabot F, Delatorre Gonzalez JC, Fournier C, Hilali S, Cambier L, Depadt G, Vert M (1986) In vivo sustained release of cisplatin from bioresorbable implants in mice. Anticancer Res 6: 1251

  15. 15.

    Hecquet B, Fournier C, Depadt G, Cappelaere P (1986) Preparation and release kinetics of microencapsulated cisplatin with ethylcellulose. J Pharm Pharmacol 36:803

  16. 16.

    Kaetsu I, Yoshida M, Asano M, Yamanaka H, Imai K, Yuasa H, Mashimo T, Suzuki K, Katakai R, Oya M (1987) Biodegradable implant composites for local therapy. J Controlled Release 6:249

  17. 17.

    Lindberg B, Lote K, Teder H (1984) Biodegradable starch microspheres — a new medical tool. In: Davis SS, Illum L, McVie JG, Thomlinson E (eds) Microspheres and drug therapy. Pharmaceutical, immunological and medical aspects. Elsevier, Amsterdam, p 153

  18. 18.

    Los G, Mutsaers PHM, Vijgh WJF van der, Baldew GS, Graaf PW de, McVie GJ (1989) Direct diffusion ofcis-diamminedichloroplatinum(II) in intraperitoneal tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380

  19. 19.

    Los G, Mutsaers PHM, Lenglet WJM, Baldew GS, McVie JG (1989) Platinum distribution in intraperitoneal tumours after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol (accepted for publication)

  20. 20.

    McLaughlin CA, Cantrell JL, Ribi E, Goldberg EP (1978) Intratumor chemotherapy with mitomycin C and components from mycobacterium in regression of line 10 tumor in guinea pigs. Cancer Res 38: 1311

  21. 21.

    Motycka K, Slavik K, Valcarova A, Cihar R, Spacek P, Kubin M (1978) Treatment of solid Gardner lymphosarcoma with methotrexate sorbed on 2-hydroxyethylmethacrylate polymer in combination with leucovorin. Neoplasia 25:217

  22. 22.

    Nagase M, Nomura T, Nakajima T (1987) Effects of intralesional versus i.p. administration of cisplatin on squamous cell carcinoma in mice. Cancer Treat Rep 71:825

  23. 23.

    Ohanian SH, Schlager SI, Goodman D (1980) Analysis of the intralesional Adriamycin-induced regression of primary and metastatic growth of line-10 guinea pig hematoma. Cancer Immunol Immunother 8:1980

  24. 24.

    Roorda WE, Boddé HE, Boer AG de, Junginger HE (1986) Synthetic hydrogels as drug delivery systems. Pharm Weekbl [Sci] 8:165

  25. 25.

    Spenlehauer G, Vert M, Benoit J-P, Chabot F, Veillard M (1988) Biodegradable cisplatin microspheres prepared by the solvent evaporation method: morphology and release characteristics. J Controlled Release 7:217

  26. 26.

    Stewart FA, Bohlken S, Begg AC, Bartelink H (1986) Renal damage in mice after treatment with cisplatinum alone or in combination with X-irradiation. Int J Radiat Oncol Biol Phys 12:927

  27. 27.

    Takahashi H, Nakazawa S, Shimura T (1985) Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg 62:120

  28. 28.

    Takahashi T, Ueda S, Kono K, Majima S (1976) Attempt at local administration of anticancer agents in the form of fat emulsions. Cancer 38:1507

  29. 29.

    Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF (1980) A new mouse tumor model system (RIF-1) for comparison of endpoint studies. JNCI 64:595

  30. 30.

    Wenzel M, Schneider M, Bier J, Benders P, Schachschneider G (1979) Concentrations of cytostatic drugs in organs and tumors: comparison after intravenous and intratumoral injection. J Cancer Res Clin Oncol 95:147

  31. 31.

    Wenzel M, Schneider M, Bier J (1980) Toxicity and cytostatic effect of PtCl2 (NH3)2 after i.v. and i.t. injection. Z Naturforsch [c] 35:848

  32. 32.

    Yu NY, Conley FK, Luck EE, Brown DM (1988) Response of murine tumors to matrix associated cisplatin intratumoral implants. NCI Monogr 6:137

Download references

Author information

Correspondence to Marc J. M. Deurloo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Deurloo, M.J.M., Bohlken, S., Kop, W. et al. Intratumoural administration of cisplatin in slow-release devices. Cancer Chemother. Pharmacol. 27, 135–140 (1990). https://doi.org/10.1007/BF00689098

Download citation

Keywords

  • Starch
  • Water Uptake
  • Tumour Growth Delay
  • Hydrogel Formulation
  • Animal Toxicity